Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor

Life Health > Health Insurance > Medicare Planning

Final Medicare Drug Plan Regs May Frustrate Some Patients

X
Your article was successfully shared with the contacts you provided.

Officials at the Centers for Medicare and Medicaid Services (CMS) have completed work on Medicare drug coverage regulations that could give the plans help with holding down drug prices.

CMS — an arm of the U.S. Department of Health and Human Services — will apply the new regulations to Medicare Part D drug plans, and to Medicare Advantage plan drug benefits.

(Related: CMS Proposes Medicare Part D Update)

Some provisions in the final regulations are supposed to give consumers more information about what drugs cost and affect how drug manufacturer rebates work.

For producers in the Medicare plan market, the provisions that may lead to the most conversations with clients might be the formulary cost management provisions.

A formulary is a list of the drugs a plan will cover.

In the past, CMS has required a Medicare drug plan formulary, or covered drug list, to include most of the available drugs in six major drug categories: antidepressants, antipsychotics, anticonvulsants, antiretrovirals, anticancer drugs, and immune system suppression drugs for transplant patients.

Now, a plan can restrict access to drugs in those categories in some cases, by, for example, letting a drug plan require many patients to try a cheaper drug before moving up to a more expensive drug. Requiring a patient to try a cheaper drug first is called “step therapy.”

In the commercial plan market, patients and providers have often resisted step therapy requirements.

To ease patient concerns about the new step therapy rules, CMS says it will speed up its process for handling patient appeals related to the kinds of drugs affected by the new rules.

Resources

A preliminary version of the final Medicare Part D and Medicare Advantage drug price regulations is available here.

— Read Drugmakers Will Have to Put Prices in Ads: Feds, on ThinkAdvisor.

— Connect with ThinkAdvisor Life/Health on LinkedIn and Twitter.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.